Podcasts about accelerating

How can data center construction projects stay on track, align all stakeholders, and accelerate speed-to-market? At DCD Connect New York, we sit down with Dr. Atif Ansar, Executive Chairman & Co-Founder, from Foresight to discuss how their platform acts as the “control tower” for data center projects—ensuring C-level executives, project teams, and supply chains are seamlessly aligned.In this conversation, we explore the biggest challenges in data center construction, the strategies that drive efficiency and scalability, and what the future holds for the industry.

Sponsored content from Shoals Technologies Group.EBOS – electrical balance of systems – includes everything that carries electricity from solar panels to the grid: wiring, switches, connector boxes and other components. It might not grab headlines, but it's the backbone of every solar and storage project, and is essential to performance, reliability and project success. In this special episode of The Energy Gang, host Ed Crooks talks with Stephen LaFleur, Senior Director of Sales for Utility-Scale Solar at Shoals Technologies Group, about why getting EBOS right is critical. Stephen explains how incorporating EBOS early in project planning helps EPCs and developers avoid delays, lower costs, and ensure long-term reliability.Connectors are just one example of an EBOS component that can cause serious issues. A recent report from HelioVolta found that 83% of projects surveyed had at least one connector-related issue, many of them due to simple installation mistakes. In one solar portfolio, connector failure and replacement costs added up to nearly 60% of annual revenues. So how can developers avoid that kind of severe cost impact? Stephen and Ed discuss. Also joining the conversation is Grant Reasor – he's an Associate Electrical Engineer for Solar PV and Storage Projects at Burns & McDonnell, the international architecture, engineering and construction firm. From a project engineer's point of view, he unpacks why EBOS matters more than ever, especially as the industry shifts to higher voltages and looks to repower aging solar sites.The solar and storage industries are evolving fast. Stephen and Grant break down how smart EBOS choices can improve efficiency, reduce risk, and support the next wave of clean energy growth.This episode is brought to you by Shoals Technologies Group. If you are in clean energy, you know that project success depends on more than just panels and batteries, it's about the electrical backbone that connects it all. That's where Shoals comes in. Their factory-built, rigorously-tested EBOS solutions for solar and storage streamline installs, reduce costs, and improve long-term reliability. Want to learn more? Just head over to shoals.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We're excited to kick off a new show focusing on the real-world AI applications that product teams are using to become faster, more efficient, and smarter. Jeff has been traveling across the country meeting product leaders, and he keeps having the same conversation: every product person wants to know how their peers are using AI in their teams and their workflows. So we're bringing you those conversations about how your peers are using AI in their day-to-day to move faster and more efficiently than ever before. In our first episode, we're welcoming back Roman Gun, VP of Product at Zeta Global. In this episode, we talk about: The prompting and workflow orchestrations Roman created to automate writing PRDs, one of the most disliked tasks of product managers, and how he has made them into living, breathing documents that initiate collaboration The AI communities and platforms he uses, including Reddit and Discord, to stay ahead, learn new tricks, and gain early access to the best new tools And Magic...not actual magic, but we have a little fun with Roman's side-project centered around Magic: The Gathering, and how he built tools to prototype new decks and beat players with far more experience Links LinkedIn: https://www.linkedin.com/in/romangun/ Zeta Global: https://zetaglobal.com/ Resources Real-world AI products with Roman Gun, VP of Product: https://www.youtube.com/watch?v=B7syxCetzHU Leader Spotlight: Right-sizing processes, with Roman Gun: https://blog.logrocket.com/product-management/leader-spotlight-roman-gun/ Inside Gemini 2.5 | Logan Kilpatrick | PodRocket: https://youtu.be/2LGKwf2xH7g Tools OpenAI: https://openai.com/ Gemini: https://gemini.google.com/ Claude: https://claude.ai/ Figma: https://www.figma.com/ Coda: https://coda.io/ Notebook LM Discorder: https://support.google.com/notebooklm/answer/16268096?hl=en&co=GENIE.Platform%3DDesktop Cursor: https://www.cursor.com/ Windsurf: https://windsurf.com/ Loveable: https://lovable.dev/ ChatGPT: https://chatgpt.com/ Chapters 00:25 AI in Action 01:27 Real-World AI Applications 02:41 Community and AI Learning 06:12 Automating PRDs with AI 11:51 Training AI for Better Outputs 14:48 Prototyping with AI Tools 16:03 Generating Baseline Code with AI Tools 16:17 The Power of Prototyping and User Feedback 16:36 Accelerating the Creative Process 18:18 Magic: The Gathering and AI Deck Building 19:28 Challenges and Innovations in AI Deck Building 21:35 Learning and Applying AI in Real Life 25:30 The Future of Junior Roles in Tech 30:21 Final Thoughts and Encouragement Follow LaunchPod on YouTube We have a new YouTube page (https://www.youtube.com/@LaunchPod.byLogRocket)! Watch full episodes of our interviews with PM leaders and subscribe! What does LogRocket do? LogRocket's Galileo AI watches user sessions for you and surfaces the technical and usability issues holding back your web and mobile apps. Understand where your users are struggling by trying it for free at LogRocket.com (https://logrocket.com/signup/?pdr). Special Guest: Roman Gun.

In this fascinating episode of Exploring the Mystical Side of Life, host Linda Lang sits down with Ken Lloyd—a former cybersecurity expert turned channel, healer, and miracle-worker—for an eye-opening conversation about spiritual awakening, walk-ins, and multi-soul experiences. Discover the difference between a "walk-in" and a "soul braid," and how soul aspects and oversouls can merge to help accelerate our collective ascension. Ken opens up about miracle healings, the challenges of releasing his old life, and his mission to ignite the spark of divinity in millions of people.Linda and Ken also explore the Library of Creation—a multidimensional resource where anyone can heal trauma, release past life energy, and access guidance beyond traditional Akashic records.Experience a live group healing with light language activations, and get practical advice for navigating intense spiritual transformation.Connect with Ken at kenloydofficial.com and learn more about Linda's work at thoughtchange.com.If you're curious about miracle healings, the ascension process, or new energetic healing tools, this episode is not to be missed! Subscribe, share, and dive deep into the mystical with us.#mystical #healing #walk-in #soulbraide #ascension #lightlanguage #energyhealing #spiritualawakening #podcast #exploringthemysticalsideoflife Subscribe and join us as we explore the deeper truths of reality, the mystical realms, connect with higher guidance, and embody more light, love, and truth in everyday life. Your support helps us explore more dimensions of spirituality and mysticism for everyone.If you'd like to buy us a cup of coffee, contributions (any amount) can be made to https://paypal.me/thoughtchange or https://www.buymeacoffee.com/s0ycsy6sj9. Thank you! We appreciate all donations. Produced by Linda Lang, ThoughtChange, Box 551 Richmond, ON, Canada K0A2Z0Disclaimer: The opinions expressed in this podcast/video are those of the guest and do not necessarily reflect the views or positions of the host or the podcast.

Matt Petit, Mission Success Lead at Vannevar Labs and former U.S. diplomat, joins Mike Shanley to accelerating national security with new technology. The conversation focuses startups and innovation in national security to deliver faster and more efficient results.   Resources: GovDiscovery AI Federal Capture Support: https://www.govdiscoveryai.com/   BIOGRAPHY: Matt Petit is a Mission Success Lead at Vannevar Labs and former U.S. diplomat. Prior to joining Vannevar, Matt spent nearly 17 years with the U.S. Foreign Service. During that time, he served in India, Zambia, and Armenia (covering Iran). While on assignments in in Washington, Matt managed foreign policy on Somalia, Eritrea, Djibouti, Sudan, and global counterterrorism. From April 2022 to July 2023, Matt was the Director for the Sahel at the White House National Security Council. Matt speaks Persian, Spanish, and some Tamil, German, and French. He lives in the DC area with his wife and daughter.   LEARN MORE: Thank you for tuning into this episode of the Global Strategy Podcast with Mike Shanley. You can learn more about working with the U.S. Government by visiting our homepage: Konektid International and GovDiscovery AI. To connect with our team directly, message the host Mike Shanley on LinkedIn.

FFB Episode 232 – Surf Internet's 200k Fiber Passings Accelerating Rural Deployment Across the Great Lakes by Fiber for Breakfast with Gary Bolton

When was the last time you truly paused to consider how far artificial intelligence has come and where it's heading next? On today's episode of Tech Talks Daily, I dive into this fast-moving frontier with Mo Cherif, Vice President of Generative AI and Innovation at Sitecore. This conversation explores what 2025 holds for agentic AI and why this technology is poised to completely reshape the marketing landscape. Agentic AI isn't just an iteration of automation; it's a rethinking of how AI can operate independently, plan, reason, and collaborate with humans to create experiences that are more tailored and impactful than ever before. In our chat, Mo shares how Sitecore, in collaboration with Microsoft, has launched the Martech industry's first AI Innovation Lab, an ambitious initiative designed to give marketers a real-world playground to prototype and validate AI-driven solutions without the fear of wasted time or sunk cost. As Mo explains, so many marketing teams are eager to embrace AI but hesitate when it comes to proving ROI and finding the right entry point. The Lab strips away that uncertainty by pairing businesses with experts and offering a safe, agile space to experiment and co-create. We unpack how agentic AI is transforming traditional customer journeys into instant, hyper-personalized interactions. Picture a world where a single conversation with a chatbot handles discovery, decision-making, and purchase, all while retaining every piece of context for a seamless experience. Mo explains why context and governance are critical pillars that organisations need to master to harness this new era of AI without compromising brand integrity. Mo also paints a picture of the future where AI co-pilots are not an add-on but an integral part of daily workflows, taking the tedious tasks off human plates and freeing teams to focus on innovation, storytelling, and strategy. It's a future where businesses don't just talk about digital transformation, they live it, powered by AI that works alongside humans, not in their place. If you've been wondering how to start your own journey with agentic AI, this conversation offers practical insights and a glimpse into Sitecore's vision of brand-aware, goal-driven AI. How ready is your organisation to rethink its content operations and customer engagement for this new reality? Tune in and ask yourself, are you prepared to lead in the age of agentic AI?

When trust becomes your agency's fastest growth lever, the game changes—and Ryan Hanley is here to prove it. In this episode, I talk with Ryan about his journey from agency owner to tech innovator and how his new venture, Linqura, is transforming the way commercial insurance agencies build trust more efficiently. We dive into the […]

You've seen the quotes. “You can have it all.” But what does that even mean? In this unfiltered episode, Rachel and David unpack the myth (and reality) of “having it all” as high-performing parents, business owners and health leaders. Here's what we dive into: Why “having it all” is relative and why most people are chasing someone else's version The identity shift required to actually get the results you say you want Why your standards (not your schedule) dictate whether you win in health, business, and life The hard truth about motherhood, burnout, and building a life that actually feels good Why most women over 35 are living boring, disconnected lives and how to fix it The concept of “social atrophy” and how it's quietly eroding your joy and confidence How to run a business, raise a family, and still feel sexy, free, and powerful If you've ever felt behind, resentful, or like you're constantly dropping the ball somewhere in your life, this one's for you. Because yes, you can have it all. Just not if you're living by someone else's rules.

On this episode, host Dave Wennergren talks with two of the ACT-IAC 2025 Innovation award winning teams. Guests:Regupathi Angappan, Postdoctoral Scientist, SandboxAQ. https://www.linkedin.com/in/regupathi-angappan-ph-d-b425185b/ Kenyon Crowley, managing director, Health Data & AI, Accenture Federal Services. https://www.linkedin.com/in/kenyoncrowley/ Additional Resources:To learn more about ACT-IAC, please visit our website: https://www.actiac.org/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In May 2025, the Emerging Technologies Institute and MITRE Corporation released a report that explores how artificial intelligence (AI) can improve the Department of Defense's acquisition system and support its workforce. Several of the authors, including Adam Bouffard (Group Leader and Principal Decision Analyst at MITRE), Chris Barlow (Senior Acquisition Analyst), and Wilson Miles (Associate Research Fellow at ETI) joined the podcast to discuss both the opportunities of inserting AI into the acquisition lifecycle and barriers to implementation. Additionally, the guests describe several potential paths forward to accelerate the adoption of AI for acquisition needs.Accelerating the Future: Leveraging AI for Transformative Federal Acquisition, https://www.emergingtechnologiesinstitute.org/publications/research-papers/accelerating-the-futureTo receive updates about the NDIA Emerging Technologies for Defense Conference and Exhibition on August 27-29, 2025 at the Washington D.C. Convention Center, please join our mailing list here: https://www.emergingtechnologiesinstitute.org/sign-up or visit our website at: https://www.ndiatechexpo.orghttps://emergingtechnologiesinstitute.orghttps://www.facebook.com/EmergingTechETIhttps://www.linkedin.com/company/ndia-eti-emerging-technologies-institute https://www.twitter.com/EmergingTechETI

Why is there an urgent need to address soil loss and explore solutions like saturated buffers, bioreactors, and advanced wetlands? Ruth McCabe, Conservation Expert, shares her optimism about reaching a tipping point in water quality and soil retention thanks to batch and build and edge-of-field practices. Hear why farmers are experiencing the positive impact firsthand, and why a new wave of passionate individuals is poised to transform agricultural landscapes for cleaner water and richer soil.Chapters:00:00 Intro00:35 Welcome00:43 Getting excited about water quality01:30 The tipping point02:20 Unsustainable soil loss03:40 Developing infrastructure05:20 Give us another ten years…06:20 Is it making a difference?07:00 Getting the farmers excited07:26 Small impact to production acres08:20 Batch and build09:20 Spreading the model beyond Iowa10:27 Thanks for joining us!Related content:#128 | Bridging the Divide: Tenant Owners, Landowners & Conservation Decisions#127 | Cover Crops and No-Till: A Conservationist's PerspectiveAg Drainage Management CoalitionHeartland Co-opFind us on social media!Facebook Twitter InstagramListen on these podcast platformsApple Podcasts Spotify YouTube MusicYouTubeVisit our website to explore more episodes & water management education.

In this episode of SaaS Fuel, Jeff Mains is joined by cybersecurity expert and SafeStack CEO Laura Bell Main to reframe how SaaS founders think about security. It's not just compliance or a checklist—it's a cultural foundation for growth. Laura shares how security, when embedded early, accelerates deals, reduces friction in enterprise sales, and strengthens trust with customers before it's ever questioned.You'll learn how to shift developer mindsets, build security into your engineering culture, and avoid the costly mistake of treating security as someone else's job.Whether you're a bootstrapped founder or VC-backed startup, this is the episode that helps futureproof your SaaS—without killing your velocity.Key Takeaways00:00 – Intro: Hiring challenges in a capital-efficient SaaS world01:47 – Why security isn't a feature—it's the foundation02:16 – Creating a dev culture where security is second nature04:00 – Guest intro: Laura Bell Main of SafeStack05:04 – Laura's cybersecurity journey and founding SafeStack08:01 – Security as culture, not compliance10:50 – Scaling to 84 countries with no ad spend13:03 – From side project to global venture14:52 – Early founder mistakes and big lessons17:06 – Culture of learning: “What I Learned Today”18:46 – Scaling support for SaaS founders20:00 – Filtering the noise and trusting your next step22:35 – Cross-cultural founder lessons25:17 – Internal culture: Balancing trust, safety, and innovation29:13 – Designing security education that actually works33:15 – Getting entire engineering teams involved36:10 – The risk of delaying security in SaaS38:28 – Accelerating enterprise sales with securityTweetable Quotes“Security isn't a task—it's a culture.” — Laura Bell Main“Most SaaS founders wait until it's too late to think about security.” — Jeff Mains“Embedding security early isn't a slowdown—it's an accelerant.” — Laura Bell Main“The cost of a bad hire is nothing compared to the cost of a poor culture.” — Jeff Mains“If 150 developers is your threshold for hiring a security person, you've waited too long.” — Laura Bell Main“Scaling a SaaS company requires fewer hacks and more habits.” — Jeff MainsSaaS Leadership LessonsSecurity Is a Culture, Not a CheckboxMaking security part of your team's DNA creates long-term growth, not short-term friction.Hire Based on Pain, Not HopeScaling prematurely can be just as dangerous as hiring too late.Start Security Early—Not After the First Enterprise DealFounders who embed security from the start build trust faster and shorten the sales cycle.Teach Security as Behavior, Not Just TheorySafeStack succeeds by focusing on culture change, not technical checklists.Global Growth Without Ads Is PossibleIf your mission is clear and execution solid, early adopters will spread the word.Your Culture Is the Greatest Risk or AssetCreate an environment where learning is daily, mistakes are shared, and trust is built top-downGuest ResourcesEmail - laura@safestack.ioWebsite - https://safestack.io/Linkedin - https://www.linkedin.com/in/laurabellmain/Episode...

Send us a textEver wondered how to tap into specialized vertical markets that offer substantial growth opportunities? Sara Marberry, a healthcare and senior living design knowledge expert, shares explore the untapped potential these sectors hold for furniture dealers and manufacturers. Listen as she shares her story as well as:Healthcare environments contain diverse spaces including clinical areas, administrative offices, and lobbiesTelehealth is creating demand for acoustically private pods and technology-enabled furnitureSenior living communities span from independent living to skilled nursing with varying furniture needs$300 billion shortfall in senior living construction expected by 2030 creates renovation opportunitiesTerminology matters – these are "communities where people live" not "facilities where people are placed"Educate yourself through industry resources, continuing education, and attending healthcare conferencesConnect with Sara:Sara Marberry LLC - https://www.saramarberry.com/Email - sara@saramarberry.comLinkedIn - https://www.linkedin.com/in/saramarberry/Connect with Sid: www.sidmeadows.comEmbark CCT on FacebookSid on LinkedInSid on InstagramSid on YouTubeSid on Clubhouse - @sidmeadowsSubscribe to my LinkedIn Newsletter. https://www.linkedin.com/newsletters/inside-contract-interiors-7298489501159460865/ The Trend Report introduction music is provided by Werq by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/4616-werq License: http://creativecommons.org/licenses/by/4.0/

In a special cross over episode the Mind Full Medic podcast is delighted to bring you this episode of the Heartline: Changemaking in Healthcare podcast with Dr Andrea Austin. I have the opportunity to flip the mic on Dr Austin, Emergency Physician and FACEP based in San Diego California, educator, simulationist, podcast host and well known to regular listeners as favourite "Frentor" of the Mind Full Medic. In this conversation we explore the fascinating world of changemaking in healthcare. As we delve into the findings of Andrea's recent research, we uncover the essential ingredients that enable healthcare professionals to become effective agents of positive transformation. Andrea sheds light on the delicate balance between individual agency and organisational support, highlighting how these elements intertwine to create an environment where meaningful change can flourish. We discuss the challenges faced by changemakers in healthcare and the strategies they employ to overcome them.Key insights from our discussion include:The importance of insatiable learning and personal growth in driving changeHow changemakers navigate the complex emotional landscape of leading transformationThe critical role of communication and listening in building coalitions for changeOrganizational strategies that foster and support changemaking effortsDiscover how to:Sustain inspiration and motivation throughout the change processDevelop the courage and resilience needed to face setbacks and oppositionLeverage organizational support to amplify your impact as a changemakerBuild and nurture the relationships crucial for successful change initiativesThis episode offers invaluable insights for healthcare professionals at all levels who aspire to make a difference in their organizations and beyond. Whether you're a seasoned leader or just starting your journey in healthcare, you'll find practical strategies and inspiration to fuel your changemaking efforts.“Changemaking is a really big part of that pathway to keeping passionate professionals engaged in healthcare.” – Dr. Andrea AustinJoin us for this thought-provoking conversation that challenges conventional thinking about change in healthcare and inspires a new generation of changemakers. Learn how small acts of courage and strategic thinking can lead to significant positive transformations in our healthcare systems.Link to the paper discussed in this episode https://www.cureus.com/articles/351909-developing-the-next-generation-of-physician-changemakers-you-have-to-love-the-people-and-love-the-process#!/Connect with Dr. Andrea Austin:https://www.linkedin.com/in/andrea-austin-simgal/Twitterhttps://www.instagram.com/andreaaustinmd/?hl=en https://podcasts.apple.com/au/podcast/heartline-changemaking-in-healthcare/id The Mind Full Medic Podcast is proudly sponsored by the MBA NSW-ACT Find out more about their service or donate today at www.mbansw.org.auDisclaimer: The content in this podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care professional. Moreover views expressed here are our own and do not necessarily reflect those of our employers or other official organisations.

The cornucopia of digital apps for healthcare administration, patient care, treatment, and optimization can be overwhelming, and the growth in AI raises questions of how far to trust each app. Mayo Clinic Platform has created a program to help health IT companies leverage Mayo Clinic Platform data, pursue clinical validation, and get their solutions deployed and adopted by healthcare organizations faster.One of the early companies to start leveraging Mayo Clinic Platform was Dock Health. We sat down for an interview with Dr. Michael Docktor, CEO at Dock Health, and Dr. Sonya Makhni, Medical Director at Mayo Clinic Platform, to learn more about the Platform and how it's helping companies like Dock Health develop solutions more quickly to better serve healthcare customers.Learn more about Mayo Clinic Platform: https://www.mayoclinicplatform.org/Health IT Community: https://www.healthcareittoday.com/

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3167: Gordon Stein explores how high-quality dividend stocks can serve as a shield against inflation while potentially accelerating portfolio growth. Highlighting examples like Lockheed Martin, Stein illustrates how dividend growth, reinvestment strategies, and careful stock selection can offer rising income and market resilience, even in volatile times. Read along with the original article(s) here: https://cashflowcookbook.com/dividend-stocks-fight-inflation/ Quotes to ponder: "Dividend stocks fight inflation with both a rising stock price and rising dividends." "A dividend growth rate that is above inflation provides income that rises faster than inflation." "Automatic reinvestment of dividends means that you will buy more as the stock price dips and buy less as the price rises, improving your overall investment." Episode references: Vanguard Dividend Appreciation Fund (NYSE:VIG): https://investor.vanguard.com/investment-products/etfs/profile/vig SPDR S&P Dividend ETF (NYSE:SDY): https://www.ssga.com/us/en/intermediary/etfs/funds/spdr-sp-500-dividend-etf-sdy Learn more about your ad choices. Visit megaphone.fm/adchoices

In this concluding episode of our deep dive into miniaturized perfusion systems, we tackle the most challenging aspect: implementing meaningful process analytical technology (PAT) at microscale while keeping costs realistic for high-throughput applications.Tom Valentin, group leader at CSEM for Automated Sample Handling, continues sharing CSEM's pioneering work in automated sample handling, revealing both the breakthrough opportunities and stubborn technical barriers that define the current state of small-scale perfusion development.Critical insights you'll gain from this episode:The PAT miniaturization challenge is about more than size: While optical density sensors work reasonably well for microbial cultures, mammalian cell applications demand more sophisticated solutions. Tom explains why viable cell density remains the "holy grail"—and how promising technologies from companies like IMEC and Inspec are pushing the boundaries, though cost-effective 96-well implementation remains elusiveSmart compromises can unlock practical solutions: Tom reveals why the industry may need to accept hybrid approaches—real-time pH and DO monitoring combined with once-daily viable cell density sampling. He also explains the unique challenges of sensor positioning in shaking deep-well plates where liquid dynamics create measurement complexitiesPartnership models that actually work for biotech innovation: Beyond the technical discussion, Tom outlines CSEM's proven collaboration approaches, including how Innoswiss funding can provide 50% cost reduction for development projects and why their 70% proposal success rate makes them an attractive R&D partner for both startups and established pharma companiesDiscover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian GiehringConnect with Tom Valentin:LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091bWebsite: www.csem.ch/enEmail: thomas.valentin@csem.chNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3167: Gordon Stein explores how high-quality dividend stocks can serve as a shield against inflation while potentially accelerating portfolio growth. Highlighting examples like Lockheed Martin, Stein illustrates how dividend growth, reinvestment strategies, and careful stock selection can offer rising income and market resilience, even in volatile times. Read along with the original article(s) here: https://cashflowcookbook.com/dividend-stocks-fight-inflation/ Quotes to ponder: "Dividend stocks fight inflation with both a rising stock price and rising dividends." "A dividend growth rate that is above inflation provides income that rises faster than inflation." "Automatic reinvestment of dividends means that you will buy more as the stock price dips and buy less as the price rises, improving your overall investment." Episode references: Vanguard Dividend Appreciation Fund (NYSE:VIG): https://investor.vanguard.com/investment-products/etfs/profile/vig SPDR S&P Dividend ETF (NYSE:SDY): https://www.ssga.com/us/en/intermediary/etfs/funds/spdr-sp-500-dividend-etf-sdy Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Spark Time, we sit down with Steve McIntyre, CEO of Agilex Biolabs, Cameron Smith, Chief Business Development Officer, Agilex Biolabs and Mike Burfield, Partner with RDI partners, a leader in Australian R&D tax services.We dive into why Australia has become a strategic hub for global biotech development, and how Agilex Biolabs is helping companies move faster, smarter, and farther with their non-clinical and clinical development, global regulatory readiness, and access to a 43.5% R&D tax rebate.From cutting-edge BioA and tox capabilities to decoding the strategic and financial advantages that most U.S. biotechs miss, this episode is packed with insight for anyone looking to stretch their runway and accelerate drug development timelines.Listen in to learn how to make Australia part of your R&D strategy.

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3167: Gordon Stein explores how high-quality dividend stocks can serve as a shield against inflation while potentially accelerating portfolio growth. Highlighting examples like Lockheed Martin, Stein illustrates how dividend growth, reinvestment strategies, and careful stock selection can offer rising income and market resilience, even in volatile times. Read along with the original article(s) here: https://cashflowcookbook.com/dividend-stocks-fight-inflation/ Quotes to ponder: "Dividend stocks fight inflation with both a rising stock price and rising dividends." "A dividend growth rate that is above inflation provides income that rises faster than inflation." "Automatic reinvestment of dividends means that you will buy more as the stock price dips and buy less as the price rises, improving your overall investment." Episode references: Vanguard Dividend Appreciation Fund (NYSE:VIG): https://investor.vanguard.com/investment-products/etfs/profile/vig SPDR S&P Dividend ETF (NYSE:SDY): https://www.ssga.com/us/en/intermediary/etfs/funds/spdr-sp-500-dividend-etf-sdy Learn more about your ad choices. Visit megaphone.fm/adchoices

Wes Cummins, CEO of Applied Digital (APLD), gives more insight into the deal his company and Coreweave (CRWV) recently signed. The company is building the data center facility in a town of 1,100 will offer 250 megawatts of power to Coreweave. Wes notes headwinds Applied Digital faced during the DeepSeek sell-off and how A.I. adoption has only accelerated since.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

In bioprocess development, the ability to rapidly screen conditions and predict scale-up performance can mean the difference between a successful therapy launch and costly delays. Today's Smart Biotech Scientist episode features Tom Valentin from CSEM, who's pioneering revolutionary approaches to miniaturized perfusion systems that could transform how we develop biologics.Tom is a group leader at CSEM for Automated Sample Handling within the Life Sciences and Industry 4.0 business unit. As a mechanical and biomedical engineer, he brings a unique cross-disciplinary perspective to solving bioprocessing's most challenging miniaturization problems.What makes this conversation essential listening:96-deep-well plates are revolutionizing perfusion development: Tom reveals how CSEM's innovative fluidic lids enable continuous medium exchange in 300-microliter volumes, potentially allowing up to 96 parallel perfusion experiments with automated liquid handlers and shaker incubatorsThree critical barriers still need solving: Despite the promise, Tom identifies the key technical challenges that must be overcome: ultra-low flow rate liquid handling (imagine exchanging 300 μL over 24 hours), effective cell retention in miniaturized systems, and cost-effective real-time biomonitoring that fits within well plate constraintsThe future of process development is automated and intelligent: From pressure-over-liquid systems to advanced sensor integration, Tom outlines how companies can achieve near-autonomous perfusion screening—but warns that current sensing limitations mean viable cell density monitoring remains the "holy grail" of small-scale perfusionThis isn't just about smaller equipment—it's about fundamentally changing how we approach process development. If you're working in cell culture optimization, process scale-up, or bioprocess automation, Tom's insights reveal both the tremendous opportunities and practical realities of implementing next-generation perfusion systems.For biotech professionals, staying ahead means embracing these high-throughput, data-rich models, allowing smarter, faster, and more predictive process development for the therapies of tomorrow.Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian GiehringConnect with Tom Valentin:LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091bWebsite: www.csem.ch/enEmail: thomas.valentin@csem.chNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

In episode 101, I sit down with Dr. Cheryl Martin, emergency physician and host of The Mind Full Medic podcast, to explore the fascinating world of changemaking in healthcare. As we delve into the findings of my recent research, we uncover the essential ingredients that enable healthcare professionals to become effective agents of positive transformation. Our conversation sheds light on the delicate balance between individual agency and organizational support, highlighting how these elements intertwine to create an environment where meaningful change can flourish. We discuss the challenges faced by changemakers in healthcare and the strategies they employ to overcome them. Key insights from our discussion include: The importance of insatiable learning and personal growth in driving change How changemakers navigate the complex emotional landscape of leading transformation The critical role of communication and listening in building coalitions for change Organizational strategies that foster and support changemaking efforts Discover how to: Sustain inspiration and motivation throughout the change process Develop the courage and resilience needed to face setbacks and opposition Leverage organizational support to amplify your impact as a changemaker Build and nurture the relationships crucial for successful change initiatives This episode offers invaluable insights for healthcare professionals at all levels who aspire to make a difference in their organizations and beyond. Whether you're a seasoned leader or just starting your journey in healthcare, you'll find practical strategies and inspiration to fuel your changemaking efforts. "Changemaking is a really big part of that pathway to keeping passionate professionals engaged in healthcare." - Dr. Andrea Austin Join us for this thought-provoking conversation that challenges conventional thinking about change in healthcare and inspires a new generation of changemakers. Learn how small acts of courage and strategic thinking can lead to significant positive transformations in our healthcare systems. The paper discussed in this episode can be found here. Connect with Dr. Andrea Austin: LinkedIn Twitter Instagram

Evénements ·      Panel à Nice organisé le 6 mai par France Deeptech, avec Sébastien Tanzilli, Sabine Mehr, Valerian Giesz et Olivier Ezratty.·     10 mai PY4AI en Italie près de Milanhttps://www.py4ai.com/·      Q-Expo à Amsterdam le 14 et 15 mai avec le keynote d'Alain Aspect.https://www.euroquic.org/q-expo/·      International Conference on Quantum Computing 2025 (ICoQC2025) à l'Institut Poincaré la semaine du 12 mai. Cette conférence était organisée par le DIM QUANTIP (dirigé par Hélène Perrin) et durait cinq jours.https://icoqc2025.sciencesconf.org/  ·      Scaling of spin qubits workshop le 16 mai à l'ENS Paris https://www.eventbrite.fr/e/scaling-of-spin-qubits-workshop-ssq-25-tickets-1217906674649·      Inauguration de la Maison du Quantique de Grenoble le 19 mai.·      Quantum Matter à Grenoble la semaine du 19 mai https://www.quantumconf.eu/2025/·      20 mai Cigref chez EDF "Quantique & géopolitique"·     Forum Teratec au Parc Floral le 21 mai ou avait lieu une session de deux heures pour présenter le rapport de l'Académie des Technologies sur le FTQC https://teratec.eu/forum/exposition.html#:~:text=Mercredi%2021%20mai%20et%20jeudi%2022%20mai%202025&text=Les%2021%20et%2022%20mai,les%20principaux%20acteurs%20du%20num%C3%A9rique.Le rapport sera publié ici : https://www.academie-technologies.fr/publications/.  France Alice&BobLa startup annonçait un investissement de $50M pour la création d'une unité de production de puces quantiques. ée de fonds récente de Alice & Bob to Build $50 Million Advanced Quantum Lab in Paris by Matt Swayne, The Quantum Insider, May 2025. Cécile Perrault d'Alice&Bob devient la nouvelle VP du consortium européen QuiC qui a renouvelé sa gouvernance fin mai 2025. https://www.linkedin.com/posts/cecileperrault_vicepresident-quantumleadership-techinnovation-activity-7331689391926542337-yUIX QuandelaQuandela annonçait le lancement de Belenos, son nouveau QPU supportant 12 photons. Quandela to Launch Belenos, Accelerating its 2030 Roadmap Toward Scalable Photonic Quantum Systems by Cierra Choucair, The Quantum Insider, May 2025. Quandela a aussi annoncé un partenariat avec la startup Taiwano-Canadienne BTQ pour étudier la création d'un système quantique de proof-of-work pour les crypto-monnaies dont le Bitcoin. https://www.quandela.com/newsroom-posts/btq-technologies-signs-mou-with-quandela-to-advance-quantum-proof-of-work-protocols/ Pasqal Pasqal est à la tête du consortium Q-PLANET validé par l'Union Européenne avec 37 partenaires de 12 pays de l'Union (Austriche, Belgique, Danemark, Finlande, France, Allemagne, Italie, Pays-Bas, Pologne, Portugal, Espagne et Suède). Il s'agit de créer des outils de pilotage des atomes. https://www.linkedin.com/posts/pasqal_chips-ju-accelerates-quantum-innovation-with-activity-7327675824646610945-GtnE/ Par ailleurs, Pasqal publiait un papier sur PulserDiff, une extension de leur outil logiciel Pulser. PulserDiff: a pulse differentiable extension for Pulser by Vytautas Abramavicius, Roland Guichard et al, arXiv, May 2025 (29 pages). Qubit PharmaceuticalsPushing the Accuracy Limit of Foundation Neural Network Models with Quantum Monte Carlo Forces and Path Integrals by Anouar Benali, Jean-Philip Piquemal et al, Qubit Pharmaceuticals, arXiv, April 2025 (16 pages).Greedy gradient-free adaptive variational quantum algorithms on a noisy intermediate scale quantum computer by César Feniou, Muhammad Hassan, Baptiste Claudon, Axel Courtat, Olivier Adjoua, Yvon Maday, Jean-Philip Piquemal, Scientific Reports, May 2025 (18 pages). Frédéric MagniezInterview mesurée de Frédéric Magniez de l'IRIF et du groupe de travail de l'académie des technologies sur le FTQC concernant les liens entre l'IA et le calcul quantique.https://telescopemag.fr/comment-lordinateur-quantique-depassera-lia/ International Google Un papier de Craig Gidney décrit comment on peut passer de 20 millions à 1 million de qubits physiques pour factoriser une clé RSA-2048 bits. How to factor 2048 bit RSA integers with less than a million noisy qubits by Craig Gidney, arXiv, May 2025 (40 pages). Dans le même temps, un papier curieux vient d'annoncer la capacité de casser des clés RSA-2048 avec un ordinateur D-Wave actuel. https://ieeexplore.ieee.org/document/10817698 Dernier rapport Anssi sur la PQChttps://cyber.gouv.fr/publications/etat-de-la-prise-en-compte-de-la-cryptographie-post-quantique QuantinuumQuantinuum “lève” un milliard de dollars au Qatar, dans le sillon du voyage de Donald Trump dans le coin. https://www.quantinuum.com/press-releases/joint-venture-to-accelerate-quantum-computing-adoption-in-qatar InfleqtionUn excellent papier de Mark Saffman qui décrit les enjeux de la scalabilité des atomes froids. Quantum computing with atomic qubit a...

Show Notes: What is Abundance? And is it a Good Thing?OverviewThis newsletter explores the concept of abundance, particularly in the context of technology, energy, and capital. It challenges debates about whether abundance is real or manageable, presenting it instead as an unstoppable force rapidly reshaping business, society, and governance. The content spans trends from explosive AI-driven startup growth and energy breakthroughs to shifts in media, venture capital, and political dynamics.Listeners will find this collection compelling because it connects broad macro forces—technology advances, energy cost collapses, investment flows—with societal and economic changes. It offers a nuanced view that acknowledges friction and obstacles but maintains optimism that abundance is already here, accelerating, and fundamentally altering the rules across multiple domains.Key Trend 1: Explosive Growth and Changing Dynamics in AI-Driven Innovation and FundingThe emergence of AI as a multiplier of human capability is driving unprecedented revenue growth in startups, reshaping the venture capital landscape, and redefining what “scale” means. Late-stage funding surges and monumental investments in AI infrastructure reflect growing confidence in AI's commercial potential.The top 10% of B2B AI startups are achieving astronomic 236% ARR growth, marking a departure from the efficiency-first era to rapid expansion and capturing “escape velocity.”The size of top-1% venture-backed exits is nearly doubling every five years, signaling massive future capital returns at the intersection of cloud, mobile, and AI platforms.Late-stage AI investments dominate funding, including mega rounds like Anthropic's $3.5B Series E, underscoring belief in scalability and profitability.Oracle's $40B commitment to Nvidia chips for OpenAI's new data center exemplifies the scale of capital pouring into AI infrastructure needed to power trillion-parameter models.The explosion of AI integration across tools, like Perplexity Labs generating complex work products or multiple AI agents collaborating on code, highlights multi-layered adoption in workflows.Key Trend 2: Energy Abundance as the Prerequisite for Sustainable Technological and Societal GrowthEnergy is the foundational “subsidy” enabling societal complexity, climate action, and advanced AI. Rapid advances in solar, nuclear, and fusion research herald a future of "energy too cheap to meter," which will be a game changer as demand explodes.Energy breakthroughs have historically powered leaps in human development—from fire to fossil fuels—and solar energy is the latest, with plummeting costs creating a tipping point.Government reform, grid modernization, and deregulation are essential to accelerate adoption and infrastructure buildout.Upcoming nuclear small modular reactors and fusion research (including AI-assisted catalyst discovery) represent critical next steps along the energy innovation trajectory.Meeting urgent energy needs is critical for climate solutions, AI's soaring compute demand, and sustaining democratic institutions and economies.Key Trend 3: Institutional Friction vs. Market-Led Speed and Execution in Technology and GovernmentWhile abundance forces press forward, friction remains, especially rooted in institutional inertia, regulatory complexity, and political coalitions. However, the market champions the agile and fast-executing players who prioritize speed over bureaucratic safety.Biden administration's infrastructure rollout illustrates government slowness: trillions in spending with slow or no visible results.Companies achieving rapid ARR growth routinely bypass “progressive coalition politics” favoring execution and iteration.Elon Musk's brief tenure in government showed the challenges of applying private-sector efficiency models to public institutions, ending with his resignation amid political conflicts.The “Abundance Agenda” calls for governance reform but faces entrenched interest-group resistance, reflecting recurring liberal factional rivalries.Key Trend 4: The Shifting Media and Information Ecosystem—From Screening to Summarizing, and the Challenge to Web ContentAI-powered search is transforming how users access information, moving from link-based discovery to AI-generated summaries that threaten traditional web traffic patterns and publisher revenue models.Google's AI Overviews and AI Mode prioritize summarization over link retrieval, reducing user clicks to websites, shifting how “the web” is monetized and accessed.This shift generates tensions as content creators face reduced traffic even as their editorial authority becomes more valuable to AI training.New protocols like Microsoft's NLWeb aim to make websites more accessible to AI agents, signaling an evolution toward AI-powered conversational interfaces.Publishers' survival depends increasingly on establishing verified fact-based content and new business models compensating their data contribution to AI.Key Trend 5: The Democratization and Accelerated Meme-ification of Venture Capital and CultureThe VC landscape, and culture at large, is increasingly shaped by rapid narrative cycles, social media algorithms, and AI-driven content creation, emphasizing hype and viral content while paradoxically increasing the importance of genuine personal connection and location.Meme coins like Fartcoin, driven by AI-generated hype, show how narrative velocity can create rapid yet often ephemeral market spikes influencing capital flows.Social media and AI have democratized “taste,” with rapid cycles of trend formation driven by platform algorithms favoring engagement over depth.Venture capital branding is evolving to embrace memes and out-of-home advertising to reach broader retail investor audiences, challenging traditional LP communication.Despite hyper-meme culture, location and face-to-face networks remain crucial as a grounding force amid accelerated, digital-first trends. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.thatwastheweek.com/subscribe

You don't need another planner. You don't need another reset. And you definitely don't need another “motivational” morning routine.  If you're a high-achieving woman who's done every program, every protocol, and STILL finds herself stuck in an all-or-nothing cycle, this episode is for you! Rachel & David Godfrey go all in on:  The real reason you can't stay consistent (and no, it's not your willpower)  Why “completion addiction” is killing your results  How tying your self-worth to productivity keeps you chasing, never arriving  The toxic lie of hustle culture masked as “discipline”  The truth about motherhood, business, and maintaining your body without burnout  You'll learn how to break the identity loop that's keeping you stuck and finally embody the version of you who doesn't fall off, because she no longer negotiates with her old self.  This is about performance, identity and finally living like the woman you say you want to be. CONNECT WITH US! At Chase Life Consulting our mission is to empower half a million female entrepreneurs and executives globally to embrace and fulfil their true potential, unapologetically.  We aim to inspire them to courageously pursue their passions, knowing who they are, what they stand for and where they are going in life.  To optimise their physical and cognitive health; elevate performance standards and ultimately become a better version of themselves. Our commitment is to support their transformation into a physically fit, compassionate, resilient, influential leader and high value woman. Accelerating their journey toward an amazing body, improved health, wealth, fulfilment and impact while creating a deeply fulfilling and inspiring life for themselves and their family. Welcome to the team - www.chaselifeconsulting.com xx

In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics. Founded in 2018 by Flagship Pioneering, Generate Biomedicines is building a “self-driving lab” that combines machine learning, cryo-electron microscopy (cryo-EM), and high-throughput wet lab automation to dramatically accelerate drug development. The conversation dives into how Generate is reimagining protein therapeutics — going beyond trial-and-error methods to a data-first, design-driven model for creating novel medicines. The team discusses the company's proprietary approach to integrating structural biology with functional data, the economic implications of reducing time-to-market from 13 years to under 9, and how their platform could unlock treatments for diseases that have been historically undruggable. They also touch on strategic partnerships, scalability, and how AI is shifting the biotech business model from artisanal science to an industrialized, data-driven enterprise.Key Points From This Episode:00:01:30 Why Generate Biomedicines is rethinking protein drug discovery from first principles00:04:40 How their structure-first approach differs from peers like AbSci and Recursion00:07:04 Using cryo-EM to build proprietary protein interaction datasets00:10:57 Traditional drug discovery is random, expensive, and inefficient — here's how Generate is changing that00:16:58 From concept to clinic in 18–24 months: Accelerating timelines through AI00:20:47 Going beyond efficiency: Unlocking access to undruggable biology00:24:48 Turning cryo-EM into a high-throughput data engine for model training00:31:20 The long-term vision: Patient-specific protein therapeutics00:40:00 Why scalability gives Generate an edge over traditional biotech00:47:52 The future of biotech as a research & development (R&D) sharing economy00:54:19 Adapting fast: Keeping pace with generative AI advances across the stack01:00:16 The KPI (key performance indicator) for platform success: Rate of improvement

IDC's Meredith Whalen, Chief Research and Data Officers shares research updates, including the IDC Global Benchmark Study on enterprise AI strategies to build the AI fueled business.

Strategists Thomas Mucha and Johnny Yu discuss US-China strategic decoupling, trade tensions, and the implications for global markets and supply chains.2:25 – Pause of US “reciprocal” tariffs on China6:00 – National security concerns and market takeaways10:10 – Impact on global supply chains15:20 – Effects on other strategic allies and international relationships23:10 – US self-isolation and long-term investment themes

In this special episode, Lex is joined by Tara Flickinger, partner at ON Partners, to discuss the critical topic of gender equity in the executive suite — drawing insights from ON Partners' 2025 Women's Report. Throughout the conversation, they explore the persistent compensation gap between men and women, the importance of salary negotiation, and the need for structured hiring practices to ensure equity across all levels. The conversation also highlights the impact of workplace flexibility, common traits of successful women in leadership, and the societal biases that affect work-life balance.Ultimately, Tara emphasizes the importance of women advocating for themselves to accelerate progress towards economic parity — but paints a hopeful picture for what's ahead. Chapters:00:00 - Unlocking gender equity in leadership: A deep dive03:50 - Unpacking the complexities of the gender pay gap08:50 - What female executives value in a compensation package12:50 - Driving change: Practical steps to improve gender equality in your company19:57 - Identifying top talent: Key leadership traits of successful women24:38 - Building an inclusive workplace: Strategies to eliminate hiring bias30:20 - Accelerating equality: What's the outlook for women in leadership?Explore all our episodes and catch the full video experience at loxo.co/podcastBecoming a Hiring Machine is brought to you by Loxo. To discover more about us, just visit loxo.co

In this episode, Dr. Jannine Krause sits down with Christian Drapeau, neurophysiology scientist and stem cell pioneer, to explore the fascinating world of plant-based stem cell activation and regenerative medicine. Christian shares his groundbreaking research on how natural plant extracts, including Klamath Lake blue-green algae and sea buckthorn, can stimulate the body's own stem cell production — enhancing the repair of organs, tissues, bones, and even the brain. From athletes seeking faster muscle recovery to those navigating cognitive decline or chronic illness, this episode offers cutting-edge insights into the body's innate healing potential. They dive into how microcirculation, gut health, and even peptide therapy work synergistically with stem cell activation to transform long-term health outcomes. Christian also introduces StemRegen, a supplement developed to safely and effectively increase circulating stem cells using plant-based protocols.

In this episode of the Hydrogen Innovators podcast, we sit down with Pierre-Etienne Franc, a global leader in hydrogen investment and infrastructure. As the CEO of Hy24, the world's largest clean hydrogen infrastructure fund, and co-founder of both FiveT Hydrogen and the Hydrogen Council, Pierre-Etienne has played a pivotal role in shaping the hydrogen economy from multiple angles: finance, policy, and industrial deployment.Pierre-Etienne walks us through his journey from launching Air Liquide's Hydrogen Energy business to spearheading multi-billion-euro investments in clean hydrogen across the full value chain. He shares key insights into how Hy24 evaluates risk, aligns diverse stakeholders, and drives large-scale deployment at speed and scale. We also unpack common misconceptions about hydrogen, explore the emerging project hotspots around the world, and reflect on the leadership qualities needed to build lasting climate infrastructure.Whether you're a policymaker, investor, entrepreneur, or student, this episode offers a rare inside look at the strategic vision and deep conviction driving one of hydrogen's most influential voices.

New electric vehicle sales here dipped last year by 24% when compared to 2023, further making a mockery of the government's target of 1 million EVs on Irish roads by 2030.A reduction in the SEAI grant and gaps in charging infrastructure fed into consumer uncertainty when it comes to making the switch from petrol and diesel vehicles.But that trend looks to be reversing this year, something that Lisa Brankin, chairman and managing director of Ford UK & Ireland, will be keen to see accelerate.She joined host Cliff Taylor in studio to discuss the challenges of going electric, her plans for the company's future, and the launch of Ford Power Promise across Ford's range of electric cars in Ireland.Also on this week's episode of Inside Business, AIB's Economic Outlook Report for May highlights how global uncertainty and an escalation in trade tariffs could lead to a slowdown in global and Irish growth in 2025 and 2026.That said, the report also points out that the Irish economy has built up a certain level of resilience to withstand a potential trade shock in the short term.AIB Chief Economist David McNamara went through the risk US tariffs and future US tax policy pose, and the outlook for 2025 and 2026.Produced by John Casey and Suzanne Brennan with JJ Vernon on sound. Hosted on Acast. See acast.com/privacy for more information.

We're talking about either the terrifying or totally mundane new world of "vibe coding" - using AI to generate code without deep technical expertise. Joining Product Manager Brian Orlando and Enterprise Business Agility Coach Om Patel for this podcast, we're happy to welcome back to the podcast Lenar Mukhamadiev, CEO of iDelsoft (https://idelsoft.com)!Listen as we discuss how this trend is changing product development, software engineering careers, and business innovation. Stick around while we argue over resistance, how vibe coding enables faster market testing and many more points, including:Accelerating time-to-market for new ideasEvolving role of professional developersUnderstanding business problems is more valuable than codingEmergence of "product engineers," or notA future where everyone is a software creator#AIinTech #ProductDevelopment #FutureOfWork= = = = = = = = = = = =YouTubeSubscribe on YouTubeAppleSpotify= = = = = = = = = = = =Toronto Is My Beat (Music Sample)By Whitewolf (Source: https://ccmixter.org/files/whitewolf225/60181)CC BY 4.0 DEED (https://creativecommons.org/licenses/by/4.0/deed.en)

Nelson Lumbres is Co-Founder at ICP Hub Philippines. ICP Hub Philippines is an incubator and accelerator for tech projects in the Philippines. ICP Hub Philippines is doing upskilling programs, trainings, hackathons, and code camps to train Filipinos in emerging tech as well as for the new Internet in the Web3 space. Know more about the programs and the community in this episode!In this episode | 01:35 Ano ang ICP Hub Philippines? | 10:30 What is ICP or Internet Computer Protocol? | 18:59 Why is ICP building a community in the Philippines? | 22:45 Who are the organizations behind? | 26:28 What are the programs of ICP Hub Philippines? | 27:43 What are example projects and MVPs done in the programs? | 33:12 Who can join the programs? | 37:22 What is the vision? | 41:03 How can listeners find more information?ICP HUB PHILIPPINES | Website: https://islacamp.ph | Facebook: https://facebook.com/ICPHubPH | Email: lumbresnelson@gmail.comTHIS EPISODE IS CO-PRODUCED BY:SPROUT SOLUTIONS | Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://sprout.ph⁠⁠⁠⁠⁠⁠⁠⁠ | Sprout Payroll Starter: ⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/SproutPayrollStarter⁠⁠⁠⁠⁠⁠⁠⁠ | APEIRON | Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://apeirongrp.com |⁠⁠⁠⁠⁠⁠⁠⁠ TWALA |Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://twala.io⁠⁠⁠⁠⁠⁠⁠⁠ | SYMPH Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://symph.co⁠⁠⁠⁠⁠⁠⁠⁠ | SECUNA Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://secuna.io⁠⁠⁠⁠⁠⁠⁠⁠ | MAROON STUDIOS Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://maroonstudios.com⁠⁠⁠⁠⁠⁠⁠⁠ | AIMHI Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://aimhi.ai⁠⁠⁠⁠⁠⁠⁠⁠CHECK OUT OUR PARTNERS | Ask Lex PH Academy: ⁠⁠⁠⁠⁠⁠⁠⁠https://asklexph.com⁠⁠⁠⁠⁠⁠⁠⁠ (5% discount on e-learning courses! Code: ALPHAXSUP) | Founders Launchpad: ⁠⁠⁠⁠⁠⁠⁠⁠https://founderslaunchpad.vc⁠⁠⁠⁠⁠⁠⁠⁠ | GumdropLab: ⁠⁠⁠⁠⁠⁠⁠⁠https://gumdroplab.com⁠⁠⁠⁠⁠⁠⁠⁠ | CloudCFO: ⁠⁠⁠⁠⁠⁠⁠⁠https://cloudcfo.ph⁠⁠⁠⁠⁠⁠⁠⁠ (Free financial assessment, process onboarding, and 6-month QuickBooks subscription! Mention: Start Up Podcast PH) | Cloverly.tech: ⁠⁠⁠⁠⁠⁠⁠⁠https://cloverly.tech |⁠⁠⁠⁠⁠⁠⁠⁠ BuddyBetes: ⁠⁠⁠⁠⁠⁠⁠⁠https://buddybetes.com⁠⁠⁠⁠⁠⁠⁠⁠ | HKB Digital Services: ⁠⁠⁠⁠⁠⁠⁠⁠https://contakt-ph.com⁠⁠⁠⁠⁠⁠⁠⁠ (10% discount on RFID Business Cards! Code: CONTAKTXSUP) | Hyperstacks: ⁠⁠⁠⁠⁠⁠⁠⁠https://hyperstacksinc.com⁠⁠⁠⁠⁠⁠⁠⁠ | OneCFO: ⁠⁠⁠⁠⁠⁠⁠⁠https://onecfoph.co⁠⁠⁠⁠⁠⁠⁠⁠ (10% discount on CFO services! Code: ONECFOXSUP) | UNAWA: ⁠⁠⁠⁠⁠⁠⁠⁠https://unawa.asia⁠⁠⁠⁠⁠⁠⁠⁠ | SkoolTek: ⁠⁠⁠⁠⁠⁠⁠⁠https://skooltek.co⁠⁠⁠⁠⁠⁠⁠⁠ | Better Support: ⁠⁠⁠⁠⁠⁠⁠⁠https://bettersupport.io⁠⁠⁠⁠⁠⁠⁠⁠ (Referral fee for anyone who can bring in new BPO clients!) | Britana: ⁠⁠⁠⁠⁠⁠⁠⁠https://britanaerp.com⁠⁠⁠⁠⁠⁠⁠⁠ | Wunderbrand: ⁠⁠⁠⁠⁠⁠⁠⁠https://wunderbrand.com⁠⁠⁠⁠⁠⁠⁠⁠ | Fail Coach: ⁠⁠⁠⁠⁠⁠⁠⁠https://fail.coach⁠⁠⁠⁠⁠⁠⁠⁠ | Drive Manila: ⁠⁠⁠⁠⁠⁠⁠⁠https://facebook.com/drivemanilaph⁠⁠⁠⁠⁠⁠⁠⁠ | EastPoint Business Outsourcing Services: ⁠⁠⁠⁠⁠⁠⁠⁠https://facebook.com/eastpointoutsourcing⁠⁠⁠⁠⁠⁠⁠⁠ | Doon: ⁠⁠⁠⁠⁠⁠⁠⁠https://doon.ph⁠⁠⁠⁠⁠⁠⁠⁠ | Hier Business Solutions: ⁠⁠⁠⁠⁠⁠⁠⁠https://hierpayroll.com⁠⁠⁠⁠⁠⁠⁠⁠ | DVCode Technologies: ⁠⁠⁠⁠⁠⁠⁠⁠https://dvcode.tech |⁠⁠⁠⁠⁠⁠⁠⁠ Mata Technologies: ⁠⁠⁠⁠⁠⁠⁠⁠https://mata.ph⁠⁠⁠⁠⁠⁠⁠⁠ | LookingFour Buy & Sell Online: ⁠⁠⁠⁠⁠⁠⁠⁠https://lookingfour.com⁠⁠⁠⁠⁠⁠⁠⁠ | NutriCoach: ⁠⁠⁠⁠⁠⁠⁠⁠https://nutricoach.com⁠⁠⁠⁠⁠⁠⁠⁠ | Uplift Code Camp: ⁠⁠⁠⁠⁠⁠⁠⁠https://upliftcodecamp.com⁠⁠⁠⁠⁠⁠⁠⁠ (5% discount on bootcamps and courses! Code: UPLIFTSTARTUPPH) | Digest PH: ⁠⁠⁠⁠⁠⁠⁠⁠https://digest.ph⁠⁠⁠⁠⁠⁠⁠⁠ (10% discount on legal services! Code: DIGESTXSUP)START UP PODCAST PH | YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/startuppodcastph⁠⁠⁠⁠⁠⁠⁠⁠ | Spotify: ⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/show/6BObuPvMfoZzdlJeb1XXVa⁠⁠⁠⁠⁠⁠⁠⁠ | Apple Podcasts: ⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/start-up-podcast/id1576462394⁠⁠⁠⁠⁠⁠⁠⁠ | Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://facebook.com/startuppodcastph⁠⁠⁠⁠⁠⁠⁠⁠ | Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠https://patreon.com/StartUpPodcastPH⁠⁠⁠⁠⁠⁠⁠⁠ | Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://phstartup.online⁠⁠⁠⁠⁠⁠⁠⁠Edited by the team at: ⁠⁠⁠⁠⁠⁠⁠⁠https://tasharivera.com

Rohit Bhargava, founder of the Non Obvious Company and IdeaPress Publishing, on augmented creativity, the human mode, and accelerated learning. Adjunct professor at Georgetown University with a background in marketing and advertising at Ogilvy and Leo Burnett, he argues the significance of live events, media literacy, and the role of the curator in the stories we tell in branding. Technology advancements and storytelling, he says are interlinked, but the future will always depend on the greatest storytellers, and in particular, those who find the non-obvious stories to tell.#Advertising #Business #Technology

This week, we discuss the U.S. fiscal pivot, soaring deficits, and what it means for bond markets, Bitcoin, and global capital flows. We also debate whether Japan is the canary in the coal mine for sovereign debt risks, if QE is still politically viable, the housing market crisis, and why Bitcoin and foreign equities may be the only rational long-term trades. Enjoy! — Follow Tyler: https://x.com/Tyler_Neville_ Follow Quinn: https://x.com/qthomp Follow Felix: https://twitter.com/fejau_inc Follow Forward Guidance: https://twitter.com/ForwardGuidance Follow Blockworks: https://twitter.com/Blockworks_ Forward Guidance Newsletter: https://blockworks.co/newsletter/forwardguidance Forward Guidance Telegram: https://t.me/+CAoZQpC-i6BjYTEx — Weekly Roundup Charts: https://drive.google.com/file/d/1zNQbt0lyXLmZQYf-56mneLpPxFNJ5y7h/view?usp=sharing — Join us at Permissionless IV June 24th - 26th. Use code FG10 for 10% OFF! https://blockworks.co/event/permissionless-iv — Blockdaemon is the gateway to the decentralized economy, securing over $110B in digital assets for 400+ institutions with blockchain nodes, APIs, MPC wallets and vaults, and staking solutions. Learn more: www.blockdaemon.com Arkham is a crypto exchange and a blockchain analytics platform. Arkham allows crypto traders and investors to look inside the wallets of the best traders, largest funds and most influential players in crypto, and then act on that information. Sign up to Arkham: https://auth.arkm.com/register?ref=blockworks Eligibility varies by jurisdiction. Users residing in certain jurisdictions will be excluded from onboarding. Echo Protocol is the first Bitcoin liquid re-staking and yield layer on MoveVM. As the second-largest protocol on Aptos by TVL, Echo secures nearly half of the network's bridged assets with ~$200M in aBTC minted. Check out https://www.echo-protocol.xyz/ to learn more! — Timestamps: (00:00) Introduction (01:46) Big Beautiful Bill (06:47) There's One Trade (09:39) Ads (Blockdaemon, Aptos, Arkham) (11:21) Government Spending Problem (14:10) US Economic Data (16:55) Housing Market Crisis (22:12) Global Collateral & JGBs (27:21) Food Prices & Labor (30:46) Ads (Blockdaemon, Aptos, Arkham) (33:10) Bond Yields & Inflation (38:32) Liquidity & Collateral Stress (42:03) US Equities Still Safe? (50:37) Final Thoughts — Disclaimer: Nothing said on Forward Guidance is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are opinions, not financial advice. Hosts and guests may hold positions in the companies, funds, or projects discussed.

Are you struggling to differentiate your channel program in a crowded cybersecurity market? Wondering how to speed up your sales cycle and create more value for partners? Curious about what it takes to scale globally with varying partner expectations? If these questions hit home, this episode offers field-tested answers and bold new strategies.In this conversation we discuss:

"If you really want to understand biology, you need to be able to represent it in the computer. If you can't model it, you can't really predict its behavior” In this episode of The Biotech Startups Podcast, Michael Antonov, Co-Founder of Oculus and Founder & CEO of Deep Origin, returns for the fourth installment of his series to share how his vision for holistic biological simulation evolved from Formic Labs into Deep Origin. Michael discusses the challenges of building a unified R&D platform for biotech, the current suite of Deep Origin's products, and how the company is making advanced drug discovery tools accessible to organizations of every size. He also dives into the company's philosophy, the lessons learned from previous ventures, and what's next as Deep Origin continues to scale its impact on the life sciences sector.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Today on the Invest In Her podcast, host Catherine Gray talks with Kim Lawton, Co-Founder and COO of Enthuse Marketing Group and the Enthuse Foundation. With over two decades of experience leading marketing campaigns for brands like Disney, Diageo, and Nestlé, Kim has made her mark as a visionary in brand strategy and female entrepreneurship. She previously co-founded Inspira Marketing and has been featured in Forbes and Fortune for her leadership in building mission-driven businesses. In this episode, Kim shares how her desire to foster female entrepreneurship led to the creation of the Enthuse Foundation, a nonprofit arm that offers support, education, and funding for women-led businesses. Catherine and Kim dive into the challenges of running a business, the importance of creating communities for female founders, and what it takes to lead with purpose in today's fast-paced marketing world. Kim also reflects on how her Midwestern roots shaped her work ethic and entrepreneurial drive. https://www.enthusefoundation.org https://www.enthuse-marketing.com https://www.showherthemoneymovie.com https://svwomenfoundersfund.vc www.sheangelinvestors.com    Follow Us On Social Facebook @sheangelinvestors Twitter (X) @sheangelsinvest Instagram @sheangelinvestors & @catherinegray_investinher LinkedIn @catherinelgray & @sheangels

An airhacks.fm conversation with Juan Fumero (@snatverk) about: tornadovm as a Java parallel framework for accelerating data parallelization on GPUs and other hardware, first GPU experiences with ELSA Winner and Voodoo cards, explanation of TornadoVM as a plugin to existing JDKs that uses Graal as a library, TornadoVM's programming model with @parallel and @reduce annotations for parallelizable code, introduction of kernel API for lower-level GPU programming, TornadoVM's ability to dynamically reconfigure and select the best hardware for workloads, implementation of LLM inference acceleration with TornadoVM, challenges in accelerating Llama models on GPUs, introduction of tensor types in TornadoVM to support FP8 and FP16 operations, shared buffer capabilities for GPU memory management, comparison of Java Vector API performance versus GPU acceleration, discussion of model quantization as a potential use case for TornadoVM, exploration of Deep Java Library (DJL) and its ND array implementation, potential standardization of tensor types in Java, integration possibilities with Project Babylon and its Code Reflection capabilities, TornadoVM's execution plans and task graphs for defining accelerated workloads, ability to run on multiple GPUs with different backends simultaneously, potential enterprise applications for LLMs in Java including model distillation for domain-specific models, discussion of Foreign Function & Memory API integration in TornadoVM, performance comparison between different GPU backends like OpenCL and CUDA, collaboration with Intel Level Zero oneAPI and integrated graphics support, future plans for RISC-V support in TornadoVM Juan Fumero on twitter: @snatverk

Sean O'Lone, former senior assistant to the Department of Navy CIO and current CTO of SAIC's Navy Business Group, joined us at Nutanix .NEXT to discuss federal modernization efforts and the future of defense IT. O'Lone served in various positions across the Navy and Joint Staff before joining industry. He shared insights into key pilot programs that modernized endpoint IT capabilities for Navy personnel, including supporting the Navy's Flank Speed. He explored the persistent challenges of federal IT modernization, from navigating budget constraints to balancing security and innovation. O'Lone explained opportunities to reduce duplication in the software enterprise to drive cost and mission efficiency, and how industry can best support the Pentagon's digital transformation.

Anne Gannon is an entrepreneur at heart. She founded The Largo Group in 2016 because of her belief that accounting needs to be done differently. Rather than an accounting firm with a hands-off approach, she structured The Largo Group to take an active role with businesses through a monthly accounting system. They first found the way into restaurants, because it's an industry that has so many variables and is the hardest accounting job. Over the past ten years, Anne has worked with over 500 companies all over the United States - ranging in revenue from $5 to $50 million. There are very few people that know more about small businesses than Anne, simply because she has spent a decade on weekly calls with owners around the country. She hears their frustrations, understands their pain points, and helps them navigate challenges while planning for the expansion phase of the business What You Will Learn: Who is Anne Gannon? What led Anne Gannon to transition from a competitive golf career to accounting? How did Anne's entrepreneurial background influence her approach to accounting? What prompted Anne to launch her own company, Largo Group, in 2016? What strategies did Anne implement to help business owners regain control during the pandemic? What role does real estate play in long-term investment strategies, according to Anne? What insights does Anne share from her book, The Real Estate Accelerator? How did the pandemic shift investor strategies from long-term rentals to short-term rentals? What advantages do short-term rentals offer compared to traditional long-term rentals? What financial benefits are investors seeing from shifting to short-term rental strategies? How do short-term rental investors approach property management differently than traditional landlords? Why is asset protection important for investors in short-term rentals? How can the legal structure of real estate investments protect owners from liability What types of business structures are most effective for real estate investors, according to Anne? What is the significance of understanding effective tax rates for business owners and investors? How does Anne define a "real estate accelerator" and its importance for investors? What insights does Anne share from her experiences with real estate investment during economic downturns? Anne shares how everyone can contact her. Additional Resources from Anne Gannon: Website: https://www.thelargogroup.com/ LinkedIn: https://www.linkedin.com/in/anne-gannon-529107148/ Facebook: https://www.facebook.com/thelargogroup Instagram: https://www.instagram.com/thelargogroup/ YouTube: https://www.youtube.com/channel/UClOZZyNtjnrogAMBOeB5n9Q/videos Attention Investors and Agents Are you looking to grow your business? Need to connect with aggressive like-minded people like yourself? We have all the right tools, knowledge, and coaching to positively effect your bottom line. Visit:http://globalinvestoragent.com/join-gia-team to see what we can offer and to schedule your FREE consultation! Our NEW book is out...order yours NOW! Global Investor Agent: How Do You Thrive Not Just Survive in a Market Shift? Get your copy here: https://amzn.to/3SV0khX HEY! You should be in class this coming Monday (MNL). It's Free and packed with actions you should take now! Here's the link to register: https://us02web.zoom.us/webinar/register/WN_sNMjT-5DTIakCFO2ronDCg

One ChatGPT search uses ten times the energy one Google Search takes, according to David Holt. He argues for energy companies to accelerate alongside A.I. developments, particularly in the nuclear and natural gas industries. David talks about the process of "removing red tape" to bolster energy growth and opportunities ahead for the sector.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

In this insightful analysis, sponsored by the A&M Consumer and Retail Group, Simbe, Mirakl, Ocampo Capital, Infios, and ClearDemand, retail experts reveal what Lowe's new AI assistant is really designed to accomplish, beyond the surface-level marketing about leaky faucets and fertilizer choices. Key Moments: 0:02 - Breaking news: Lowe's introduces MyLow Companion AI assistant for store associates 0:10 - Partnership details: Application developed with OpenAI across 1,700+ stores 0:14 - Core functionalities: Product details, project advice, and inventory information access 0:18 - Key benefit: Accelerating the employee onboarding process 0:27 - Scale achievement: "First retailer to successfully implement this type of technology at scale" 0:33 - Technical capabilities: Generative AI with natural conversational prompts and voice-to-text 0:42 - Example use cases: Fertilizer recommendations and home repair guidance 1:14 - Ben Millers's analysis: Why this is "a great use case for AI" in categories requiring expertise 1:38 - Customer service challenge: Associates' varying experience levels and knowledge gaps 1:50 - Consistency benefit: Creating uniform quality of information regardless of associate tenure 2:00 - Comparison to self-checkout: Options for customers who prefer different service models 2:22 - Anne Mezzenga's critique of the media reporting: Overlooking the more significant training use case 2:42 - Inside information: Conversation with a Lowe's executive reveals true onboarding purpose 2:56 - Real examples: New employees quickly learning shipment timing and warranty information 3:03 - Data collection value: Using interaction data to improve future associate training 3:12 - Customer perspective: Why shoppers wouldn't ask a teenage summer employee about complex repairs 3:40 - Chris Walton's agreement: "100% I'd look this up myself" rather than wait for an associate 4:00 - PR criticism 4:20 - Industry impact concern: Creating false expectations about AI tools for retail associates 4:43 - Higher-value application: Supporting complex high-consideration sales like flooring installations 4:54 - Advanced capability: Prompting associates to ask the right questions based on customer responses 5:01 - Integration potential: Connecting to loyalty programs to enhance personalized selling The experts conclude that while Lowe's marketing focuses on answering simple product questions, the real innovation is in employee training, knowledge management, and creating consistency across a large retail workforce. Catch the full episode here: https://youtu.be/BrQ0kfPY4LA #loweshomeimprovement #ai #retailnews #retailtech #retailstrategy #retailtrends

Erik Townsend and Patrick Ceresna welcome Dr. Anas Alhajji to the show to discuss OPEC+ production increase & market reactions, Trump's visit and oil politics, and the long-term outlook for oil and LNG  & much more. https://bit.ly/43ldvBg What Do Saudi Arabia & Allies in OPEC+ Want from Accelerating the Unwinding of Voluntary Cuts? - Anas Alhajji   

SOFcast | Season 6, Episode 2: Melissa Johnson — Accelerating Innovation for SOF

Accelerating culture begins with a clearly defined purpose statement. In this episode former CFO and current President and COO of Coke Consolidated, Dave Katz, and I discuss the importance of organizational purpose statements and what it takes to build a thriving, purpose-driven culture inside a rapidly growing organization. Special thanks to our sponsor Belay for offering a FREE resource: Five Blind Spots That Sink Your Leadership. This resource provides valuable insights on the hidden habits that could be harming your leadership, and practical steps on how to address them through the power of delegation. Text the word 'Andy' to 55123 to claim your offer. Recognized as one of Forbes' 6 Leadership Podcasts To Listen To In 2024 and one of the Best Leadership Podcasts To Stay in the Know for CEOs, according to Industry Leader Magazine. If this podcast has made you a better leader, you can help it by leaving a quick Spotify or Apple Podcasts review. You can visit Spotify or Apple Podcasts, and then go to the “Reviews” section. Thank you for sharing! ____________ Where to find Andy: Instagram: @andy_stanley Facebook: Andy Stanley Official X: @andystanley YouTube: @AndyStanleyOfficial See omnystudio.com/listener for privacy information.